髓源抑制性细胞:肿瘤中西医结合免疫治疗的新靶点

发布时间：2018-02-03 17:06

本文关键词： 髓源抑制性细胞免疫抑制肿瘤中医药　出处：《中华中医药学刊》2015年11期 　论文类型：期刊论文

【摘要】：髓源抑制性细胞(myeloid-derived suppressor cells,MDSCs)是一类未成熟骨髓细胞在多种病理情况下分化成熟受阻而形成的异质细胞群体。其在肿瘤微环境中通过JAK-STAT、NF-κB等通路发生大量扩增募集及活化效应,并在慢性炎症因子、细胞因子及机体免疫细胞等复杂网状关系作用下产生免疫抑制作用,具有免疫抑制作用,贯穿肿瘤发生发展的全过程。随着中医药的国际化,相关中药及方剂已证实可通过影响髓源抑制性细胞的扩增募集及活化进程发挥其抗肿瘤作用。中药提取物结合西药靶向调控MDSCs治疗策略具有巨大潜力。
[Abstract]:Myeloid-derived suppressor cells. MDSCs are a group of heterogeneous cells formed by immature bone marrow cells which are differentiated and mature in many pathological conditions. They pass through JAK-STAT in tumor microenvironment. NF- 魏 B and other pathways have a large number of amplification recruitment and activation effects, and in the chronic inflammatory factors, cytokines and immune cells and other complex network of the role of immunosuppressive effect, with immunosuppressive effect. It runs through the whole process of tumorigenesis and development. With the internationalization of traditional Chinese medicine. Related Chinese medicines and prescriptions have proved that they can exert their antitumor effects by affecting the process of expansion, recruitment and activation of myelogenous inhibitory cells. The Chinese medicine extract combined with western medicine targeted regulation of MDSCs therapy strategy has great potential.
【作者单位】：浙江省立同德医院;
【基金】：浙江省自然科学基金项目(LY12H27012)
【分类号】：R730.59
【正文快照】： 免疫治疗在目前肿瘤治疗的地位举足轻重。随着肿瘤免疫逃逸研究的不断深入与进展,人们认识到骨髓细胞中部分未成熟细胞(immature-myeloid cells,IMCs)在肿瘤生长的过程中分化会受到抑制,最终不能分化为树突状细胞、粒细胞或巨噬细胞,从而在未成熟骨髓细胞与分化完全的细胞之间

【参考文献】